GLP-1 safety

The FDA Warned Novo Nordisk About Safety Reporting. Here Is Why Your Doctor Matters More Than Your Drug.

The FDA warning was about safety reporting, not proof that semaglutide caused deaths. A physician explains why medical follow-up matters during GLP-1 treatment.

Élan Clinic · Educational article · Published April 9, 2026

On March 5, 2026, the U.S. Food and Drug Administration issued a formal warning letter to Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, citing what it called "serious violations" in post-marketing safety reporting. Specifically, the FDA found that Novo Nordisk had failed to report three patient deaths within the agency's required timeframe. One of those deaths was a suicide that the company allegedly neither investigated nor reported at all.

This is not a headline designed to frighten you. It is an invitation to understand what pharmaceutical oversight actually looks like, and why your relationship with a physician is not a luxury add-on to GLP-1 therapy. It is the single most important safety mechanism you have.

What the FDA Actually Found

The warning letter, addressed to Novo Nordisk's U.S. subsidiary and based on a 2025 inspection of its New Jersey pharmacovigilance facility, focused on post-marketing adverse drug experience (ADE) reporting. Under U.S. federal law, pharmaceutical companies are required to collect, investigate, and submit reports of serious adverse events, including deaths, to the FDA within strict timeframes. These reports are how regulators monitor a drug's real-world safety profile long after clinical trials have ended.

The FDA was explicit on one critical point: it did not conclude that semaglutide caused these deaths. The violations were procedural, failures of reporting infrastructure, not evidence of a new danger lurking in the drug itself. The agency wrote, verbatim: "FDA relies on the complete, accurate, and timely submission of ADEs to monitor a product's safety profile and uphold FDA's mission to protect and promote public health."

Novo Nordisk acknowledged the findings and stated it is working "diligently" to address them.

Why This Matters, Even If the Drug Is Safe

Semaglutide's efficacy data remain robust. The STEP 1 trial (Wilding et al., NEJM, 2021) demonstrated approximately 15% mean body weight reduction over 68 weeks. Cardiovascular benefit is established through the SELECT trial (Lincoff AM et al., NEJM, 2023). The drug works. That has not changed.

But here is the structural problem this warning letter reveals: pharmaceutical companies are not your physician. Their relationship to your safety is mediated by spreadsheets, regulatory dossiers, and pharmacovigilance teams processing thousands of reports. They learn about your adverse event, if they learn about it at all, through a chain of reporting that can take weeks or months, and as we now know, sometimes fails entirely.

Your doctor, by contrast, sees your face.

The Gap Between Population Data and Your Body

GLP-1 receptor agonists are extraordinarily well-studied. But every clinical trial in history has been conducted on a population, not on you. The STEP and SELECT trials enrolled carefully screened participants over defined periods. Your history, your thyroid status, your family history of pancreatitis, your cardiovascular risk profile, your prior psychiatric history, your muscle mass, your current medications, none of that was accounted for in the aggregate data that got this drug approved.

This is not a flaw in the science. It is simply the reality of how medicine works. Population data tells us what a drug does, on average, to people somewhat like you. Your physician's job is to apply that knowledge to you specifically, and to monitor what actually happens.

That monitoring matters more than most patients realise:

Baseline labs. Before initiating GLP-1 therapy, a responsible clinician assesses renal function, liver enzymes, thyroid function, HbA1c, lipids, and, where indicated, resting heart rate and cardiovascular markers. These are not bureaucratic checkboxes. They establish your individual risk profile and provide the baseline against which future changes are measured.

Dose titration. The side effect profile of semaglutide is heavily front-loaded: nausea, vomiting, and gastrointestinal distress are most pronounced during the early titration phase. Experienced clinical oversight can distinguish transient adaptation from a signal requiring dose adjustment or discontinuation.

Psychiatric surveillance. The FDA warning letter specifically cited a patient death by suicide that Novo Nordisk failed to investigate or report. The relationship between GLP-1 agents and mental health is nuanced, a 2024 pharmacoepidemiological study by Sodhi et al. (Nature Medicine, 2024; n=107,910) actually found semaglutide associated with a 49-73% lower risk of suicidal ideation compared to non-GLP-1 controls. But that does not mean psychiatric risk is irrelevant. Patients undergoing rapid metabolic change, significant weight loss, and altered appetite signalling deserve ongoing attention to their psychological wellbeing, and where mental health concerns arise, clear referral pathways to psychiatric or psychological support are part of responsible clinical care. A pharmacovigilance database in New Jersey cannot provide that. A physician who knows you can.

Muscle preservation and body composition. GLP-1 medications induce weight loss without discriminating between fat mass and lean mass. Without structured follow-up, resistance training guidance, adequate protein targets, and body composition monitoring, patients can lose clinically significant amounts of muscle alongside fat, undermining long-term metabolic health. This is not captured in a drug label. It requires a clinical relationship.

The cessation problem. The STEP 1 withdrawal extension (Wilding et al., Diabetes, Obesity and Metabolism, 2022) showed that approximately two-thirds of weight lost on semaglutide was regained within 12 months of discontinuation. This is not a failure of the drug, it reflects the chronic, relapsing nature of obesity. But it means that patients who stop medication without a plan, without a maintained relationship with their care team, and without lifestyle foundations in place are likely to regain weight and return to baseline metabolic risk. Knowing when and how to stop, titrate, or transition therapy is a clinical judgment. It cannot be delegated to an app or a pharmacy subscription.

The Point Is Not Fear. The Point Is Structure.

The FDA warning letter is not evidence that semaglutide is dangerous. It is evidence that the pharmaceutical industry's pharmacovigilance infrastructure, however well-resourced, has structural gaps. It processes adverse events in aggregate, after the fact, through systems that, as we now know, can miss even a death.

What it cannot replicate is a physician who knows your name, reviews your labs, asks how you are sleeping, notices that you seem low, and adjusts your treatment accordingly.

At Élan Clinic, GLP-1 therapy is embedded in exactly this kind of relationship. Baseline assessment, regular follow-up, lab monitoring, body composition monitoring, and psychiatric attentiveness, including referral pathways to appropriate mental health support where needed, are not optional features. They are the architecture of safe, effective treatment.

The drug is a tool. The physician relationship is the safety net.

If you are considering semaglutide or Mounjaro (tirzepatide), or if you are already on treatment and managing it alone, the question is not whether the medication is effective. The question is whether you have the clinical structure around you that gives it the best chance of working safely and sustainably.

That structure is what we provide.

Élan Clinic offers physician-led weight management in Tallinn, Estonia. Both Wegovy (semaglutide) and Mounjaro (tirzepatide) are available in Estonia, you do not need to travel abroad for supervised GLP-1 treatment. Dr. Ingmar Lindström is a licensed physician and family medicine specialist with over 20 years of clinical experience. Book a 30-minute initial assessment, we'll review your health history and determine whether GLP-1 therapy is right for you. Contact us at [elanclinic.ee](https://elanclinic.ee).

References:

If you are considering GLP-1 treatment or changing your current plan, book a medical consultation with Élan Clinic. We will assess indications, risks, monitoring needs, and a realistic maintenance plan.